|Chemical and physical data|
|Molar mass||442.607 g·mol−1|
SAGE-718 is experimental drug being investigated for the treatment of neurological disorders and cognitive impairment. It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition. SAGE-718 is an analog of the neurosteroid 24S-hydroxycholesterol.
As of 2022, SAGE-718 is in Phase II clinical trials for Alzheimer's disease, Parkinson's disease, and Huntington's disease.